y90 basiliximab
mAbexperimentalADC
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Nov 9, 2012 (NCT01476839)
Timeline
2010s
- Jan 1, 2012
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Peripheral myelin protein 22INHIBITOR
PMP22 inhibitor
Chemistry & pharmacology
- Multi-specific
- No
- Payload
- 90-Yttrium
Oral
No
Parenteral
No
Topical
No
Also known as
- y90 basiliximab
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05139004 | Phase 1 | Dec 15, 2021 | City of Hope National Medical Center, National Cancer Institute (NCI) |
| NCT02342782 | Phase 1 | Jun 8, 2015 | City of Hope National Medical Center, National Cancer Institute (NCI) |
| NCT01476839 | Phase 1 | Nov 9, 2012 | City of Hope National Medical Center, National Cancer Institute (NCI) |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| City of Hope National Medical Center | Academic/Hospital | 3 | 3 | 1 | 2012 |
| National Cancer Institute (NCI) | Government | 3 | 0 | 1 | 2012 |
2 organizations
Page 1 / 1